A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

Verified Market Research® a leading provider of business intelligence and market analysis is thrilled to announce the release of its comprehensive report on the, "Mental Health Apps Market Size and ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants.

The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...

The company said that the nasal spray is a ketamine-derived drug, first approved in 2019, to be used in combination with ...

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...

Johnson & Johnson has secured FDA approval for expanded use of its Spravato nasal spray, now cleared as a standalone ...